Captopril NDC 11788-135

NDC codes

FDA NDC Directory

Product NDC (as listed)11788-135Labeler and product segments. Claims need a package NDC.

Product NDC at billing width11788-0135Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
11788-135-01	11788013501	100 TABLET in 1 BOTTLE (11788-135-01)Marketed from Apr 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Captopril
Generic name (nonproprietary): captopril
Active ingredients: Captopril — 12.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: AiPing Pharmaceutical, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214442
Marketing start: Apr 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 11788-135_8e531d13-c832-4fc0-a405-d63050458879SPL ID 8e531d13-c832-4fc0-a405-d63050458879SPL set ID 3b789f16-b291-4012-be39-af3beec3ff9aRxCUI 308962, 308963, 308964, 317173UNII 9G64RSX1XDUPC 0311788138015, 0311788136011, 0311788135014, 0311788137018
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N411788013501 followed by a unit qualifier and the quantity

Package 11788-0135-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensiv…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214442

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214442
Product	Strength	Form · route	Labeler	Product NDC
Captopril	Captopril 50 mg/1	TabletOral	AiPing Pharmaceutical, Inc.	11788-137
Captopril	Captopril 25 mg/1	TabletOral	AiPing Pharmaceutical, Inc.	11788-136
Captopril	Captopril 100 mg/1	TabletOral	AiPing Pharmaceutical, Inc.	11788-138